W. Chin

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

R. Santos, J. Guyton, P. Duell, 2013, European heart journal.

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders

P. Humaidan, T. D’Hooghe, S. Longobardi, 2017, Human reproduction.

Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders

P. Humaidan, T. D’Hooghe, S. Longobardi, 2017, Human reproduction.

Predicting live birth for poor ovarian responders: the PROsPeR concept.

P. Lehert, P. Humaidan, T. D’Hooghe, 2018, Reproductive biomedicine online.

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

D. Gaudet, D. Tribble, E. Stein, 2012, Circulation.

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.

W. Cromwell, Joann D Flaim, G. Thomas, 2013, Journal of the American College of Cardiology.

Treatment with mipomersen reduces levels of apoB-containing lipoproteins by increasing fractional removal of VLDL and LDL-apoB without reducing vldl-apob secretion

R. Morey, B. Baker, H. Ginsberg, 2014 .